News

27October2015

Nordion and Bruce Power announce MOU for the supply of medical-grade Cobalt 60

Nordion and Bruce Power two of Canada’s innovative nuclear sector companies (and iia Members) are once again strengthening their established strong partnership and respective strengths, to create a new, long-term supply of an important cancer-treating isotope, Cobalt-60, that will benefit healthcare patients in Canada and around the world.

Nordion, a standalone business within Sterigenics International, and Bruce Power announced today that they have executed a Memorandum of Understanding (MOU) for the supply of High Specific Activity (“HSA”) Cobalt-60, also referred to as medical-grade Cobalt. This type of Cobalt-60 is produced in a limited number of nuclear reactors globally and used in radiation-based treatment of cancer and other diseases in Canada and around the world.

High Specific Activity (HSA) Cobalt is typically used for relatively small, high intensity radioactive sources. These applications include non-invasive radiosurgery for the precise treatment of brain tumors as well as other external beam therapies that are used to treat more general cancer tumors in the body. Because of the precision required for these lifesaving therapies, the radioactive sources need to be small enough to provide the accuracy of dose for the required treatment while still being strong enough to provide a reasonable treatment time for patients. HSA Cobalt-60 cancer treatments, partly pioneered in Canada, have been used for more than 60 years to treat these kinds of diseases in an estimated 35 million patients worldwide.

For the Full Press Release click on the link